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RNA-guided, engineered nucleases derived from the prokary-
otic adaptive immune systemCRISPR-Cas represent a powerful
platform for gene deletion and editing. When used as a thera-
peutic approach, direct delivery of Cas9 protein and single-
guide RNA (sgRNA) could circumvent the safety issues asso-
ciated with plasmid delivery and therefore represents an
attractive tool for precision genome engineering. Gene deletion
or editing in adipose tissue to enhance its energy expenditure,
fatty acid oxidation, and secretion of bioactive factors through a
“browning” process presents a potential therapeutic strategy to
alleviate metabolic disease. Here, we developed “CRISPR-deliv-
ery particles,” denotedCriPs, composed of nano-size complexes
of Cas9 protein and sgRNA that are coated with an amphipathic
peptide called Endo-Porter that mediates entry into cells. Effi-
cient CRISPR-Cas9–mediated gene deletion of ectopically
expressed GFP by CriPs was achieved in multiple cell types,
including a macrophage cell line, primary macrophages, and
primary pre-adipocytes. Significant GFP loss was also observed
in peritoneal exudate cells with minimum systemic toxicity in
GFP-expressing mice following intraperitoneal injection of
CriPs containing Gfp-targeting sgRNA. Furthermore, disrup-
tion of a nuclear co-repressor of catabolism, the Nrip1 gene, in
white adipocytes by CriPs enhanced adipocyte browning with a
marked increase of uncoupling protein 1 (UCP1) expression. Of
note, the CriP-mediatedNrip1 deletion did not produce detect-
able off-target effects. We conclude that CriPs offer an effective
Cas9 and sgRNA delivery system for ablating targeted gene
products in cultured cells and in vivo, providing a potential ther-
apeutic strategy for metabolic disease.
Gene editing based on the CRISPR-associated protein 9
(Cas9) system presents significant therapeutic potential for
treating a wide range of diseases (1–4). The CRISPR-Cas9 sys-
tem, containing the RNA-guided nuclease (Cas9 protein) and a
single-guide RNA (sgRNA),2 recognizes a protospacer-adja-
cent motif (PAM) and generates dsDNA breaks at 3 bp
upstreamofaPAMsite(5).dsDNAbreaksarerepairedbynonho-
mologous end joining to generate permanent gene deletion by
inducing random insertions and deletions (indels) and by ho-
mology-directed repair to correct gene mutations with the use
of a guide template DNA (5). A key challenge for CRISPR-
Cas9–based therapeutics is the efficient, safe delivery of
genome editing macromolecules to achieve eventual transla-
tion to clinical efficacy and safety (6–9). Viral vectors, including
adeno-associated virus (AAV), have shown efficient in vivo
delivery and expression of CRISPR-Cas9 (10–13). However, it
is difficult to fit coding sequences for Streptococcus pyogenes
Cas9 (SpCas9) plus sgRNAs into AAV vectors due to the
restricted packaging capacity of AAVs (14). AAV-based Cas9
delivery also tends to cause significant off-target genome dam-
age due to the sustained expression ofCas9 (15, 16). In addition,
the immune response to AAV capsids and the immunogenicity
of the long-term existing bacterial Cas9 protein can limit their
applications in humans (11). Physical delivery approaches of
CRISPR-Cas9, such as electroporation (17–19), microinjection
(20), and hydrodynamic injection (21, 22), have also been suc-
cessfully used, but with concerns such as cell viability, toxicity,
and difficulty to apply in vivo.
The limitations associated with both viral delivery and phys-
ical delivery can be addressed using nonviral delivery systems,
such as lipid nanoparticles (23–27), DNA nanoclew (28), and
gold nanoparticles (29, 30), as well as chemically conjugating
Cas9 protein with polymers (31) and cell-penetrating peptides
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(32). Furthermore, direct delivery of Cas9–sgRNA ribonucleo-
protein (RNP) is being considered as a promising therapeutic
strategy. Cas9–sgRNA RNP delivery could circumvent the
safety problems associated with plasmid delivery, such as
uncontrolled integration of DNA segments into the host
genome and unwanted immune response to plasmids encoding
Cas9 protein and sgRNA (6). Therefore, nonviral delivery of
Cas9–sgRNA RNP represents an attractive tool for genome
engineering. Cas9–sgRNA RNP delivered by nonviral delivery
systems has been tested in cell culture (30, 33), primary cells
(15, 19) and for local delivery such as inner ear injection (4, 23),
skin injection (18), intratumor injection (28, 34), intramuscular
injection (29), and intracranial injection (35). Systemic admin-
istration of Cas9 mRNA and sgRNA loaded into a lipid nano-
particle has been reported to achieve robust and persistent
genome editing in vivo (24), but Cas9–sgRNA RNPs have not
been used systemically in vivo using a fully nonviral delivery
system.
Application of CRISPR in therapies for type 2 diabetes would
be attractive because this malady and its complications afflicts
around 30 million adults in the United States and is a leading
cause of death (36). White adipose tissue (WAT) stores triglyc-
erides and expands greatly during the onset of obesity, which
can prompt insulin resistance, failure of insulin secretion, and
the development of type 2 diabetes (37). Unlike WAT, brown
adipose tissue (BAT) is composed of brown adipocytes that
display a high capacity for fat oxidation and a high number of
mitochondria containing uncoupling protein 1 (UCP1) for
nonshivering thermogenesis that plays a beneficial role in
metabolism (38). BAT can also secrete beneficial factors to
increase glucose uptake and fatty acid oxidation in other tissues
(39, 40). Recent data indicate that increased BAT can favorably
control whole-body glucose homeostasis and is associated with
lean, insulin-sensitive phenotypes (41–43). White adipocytes
can be converted to brown or “beige” adipocytes by silencing
molecular targets that suppress energy expenditure, fatty acid
oxidation, and insulin signaling, such as the nuclear co-repres-
sor Nrip1 gene (44, 45) (also denoted as RIP140). Nrip1 silenc-
ing by RNAi in white adipocytes leads to adipocyte “browning”
and enhances fatty acid oxidation, mitochondrial respiration,
and insulin-mediated glucose uptake (44). Nrip1 null mice
present lean phenotypes with improved insulin sensitivity and
glucose tolerance (46), suggesting thatNrip1may be a powerful
molecular target for alleviating type 2 diabetes and obesity.
Here, we developed a novel CRISPR delivery system, denoted
CRISPR-delivery particles (CriPs), composed of nano-size
complexes of the CRISPR components Cas9 protein and
sgRNA targeting a gene of interest, complexed with an Endo-
Porter (EP) peptide through electrostatic complexation. EP is
an amphipathic -helical peptide composed of leucine and his-
tidine residues. It is hypothesized that the weak-base histidine
residues of EP facilitate the endosomal escape of the cargoes by
permeabilizing the endosomal membrane upon acidification
within the endosome, known as the “proton-sponge effect”
(47). We have previously shown that EP is a crucial component
of the -1,3-D-glucan-encapsulated siRNA particles (GeRPs)
and is required for efficient GeRP-mediated siRNA delivery
(48–51). As proof of concept, efficient CRISPR-Cas9–
mediated gene deletion of the GFP gene (Gfp) was observed in
multiple cell types isolated from GFP transgenic mice, includ-
ing primary macrophages and primary pre-adipocytes. GFP
loss was achieved in about 50% of macrophages and primary
pre-adipocytes as determined by flow cytometry analysis, in
response to treatment with CriPs targeting Gfp. Indels in the
Gfp genomic locus were confirmed by measurements using a
T7 endonuclease I (T7E1) assay. Significant GFP loss was also
observed in peritoneal exudate cells (PECs) isolated from GFP
transgenic mice after five daily intraperitoneal (i.p.) injections
with CriPs targeting Gfp, as determined by flow cytometry and
confirmed by nucleotide sequencing. Furthermore, deletion of
theNrip1 gene in white adipocytes by CriPs converted them to
a more “brown” adipocyte phenotype, with a remarkable
increase of UCP1 expression and no detectable off-target
effects as determined by a T7E1 assay.
Results
Design and characterization of CriPs
The goal of the present studywas to develop a simple delivery
vehicle to effect specific gene deletion via the CRISPR-Cas9–
based genome targeting mechanism. For therapeutic applica-
tions, we aimed to directly deliver Cas9 protein rather than
plasmids that encode the protein to overcome such problems as
uncontrolled integration of plasmid DNA into the host
genome, unwanted immune responses, and safety issues. Here,
we report the preparation of CriPs that can deliver Cas9 protein
bound to sgRNA to mediate gene deletion in vitro and in vivo
(Fig. 1). Purified bacterial Cas9 protein that is carefully pro-
cessed to remove endotoxin and other contaminants is used for
loading of sgRNA. The sgRNA sequence is designed to target a
selected gene at a site adjacent to a PAM sequence in the DNA
of that target gene. The loaded Cas9–sgRNA complexes are
then electrostatically complexed with amphipathic EP peptide,
which is designed to mediate the uptake of the Cas9–sgRNA
complexes into live cells without toxicity or detectable damage.
The inert CriPs contain only the three molecular components
shown in Fig. 1 (Cas9 protein, sgRNA, and EP). As opposed to
gene therapy approaches, no permanent viral vectors or genetic
insertions of viral DNA are utilized. Cas9 protein that enters
cells through transfectionmechanisms lasts no longer than 24 h
Figure 1. Preparation of CriPs. Purified bacterial Cas9 protein that is care-
fully processed to removeendotoxin andother contaminants is used for load-
ing of sgRNA. The sgRNA sequence is designed to target a selected gene at a
site adjacent to a PAM sequence in the DNA of that target gene. The loaded
Cas9–sgRNA nanocomplexes are then coated with an amphipathic peptide,
denoted as EP, which is required tomediate uptake of the Cas9–sgRNA com-
plexes into live cells without toxicity or detectable damage.
Cas9–sgRNA delivery particles for gene deletion
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within cells (52). The EP peptide and the sgRNA is also
expected to be rapidly degraded within cells. Thus, for ex vivo
therapeutic approaches such as cell therapy and transplanta-
tion of ex vivo engineered tissue, Cas9 and other components in
CriPs are not present in cells that are implanted. Additionally,
unlike RNAi-based approaches, CriP-mediated gene editing
lasts for the lifespan of a cell, which allows for less frequent
therapeutic administration and less chance of immune
response or chronic toxicity.
CriPs with different ratios of EP to Cas9–sgRNA complexes
were prepared and measured for their sizes and charges (Table
1). Dynamic light scattering (DLS) measurements showed that
the average hydrodynamic sizes of EP, Cas9, and Cas9–sgRNA
(1:1) were 0.8 0.2, 9.3 2.6, and 14.3 3.2 nm, respectively.
The hydrodynamic size of the CriPs consisting of Cas9–
sgRNA–EP (1:1:20) was 375  47 nm. The sizes of the CriPs
were further increased when coated with more EPs, suggesting
that each particle contains multiple Cas9–sgRNA complexes
associated with EP peptides. The sizes of CriPs remained
unchanged with dilution in Dulbecco’s modified Eagle’s medium
(DMEM), which mimics the in vitro cell culture conditions, sug-
gesting the stability of the particles in the culture media.
 potentials of the particles were also measured. Positive
charges of6.0 4.4,14.6 6.3, and20.7 6.0 mV were
observed for the CriPs loaded with Cas9–sgRNA–EP with a
molar ratio at 1:1:20, 1:1:150, and 1:1:250, respectively. The
overall positive charge on the surface of the particles could
facilitate cellular uptake by interacting with the negatively
charged cell membranes.
Deletion of Gfp in amacrophage cell line by CriPs
To investigate whether CriPs can efficiently delete genes in
vitro, we first treated a macrophage cell line, J774A.1, which
stably expresses GFP (GFP-J774A.1), with CriPs loaded with
sgRNA targeting the Gfp gene (Gfp sgRNA). The targeting
sgRNA directed to Gfp is designed to introduce an indel muta-
tion that results in a frameshift and termination ofGfp transla-
tion. CriPs were incubated with GFP-J774A.1 cells, and the loss
of GFP signal was determined by flow cytometry. 7-Amino-
actinomycin D (7-AAD) staining was used to distinguish
among viable cells and dead cells. Percentages of GFP-negative
cells and GFP-positive cells were calculated from the live cells.
At 48 h post-treatment, CriPs loaded with Gfp sgRNA (Cas9–
Gfp sgRNA–EP) induced a shift of the GFP signal in 54.0% of
theGFP-J774A.1 cells (Fig. 2A and Fig. S1). The shift of theGFP
signal rather than the complete loss of GFP after 48 h of treat-
ment was due to the slow degradation of the GFP protein. On
day 5 post-treatment, CriPs loadedwithGfp sgRNA (Cas9–Gfp
sgRNA–EP) caused a loss of the GFP signal in 55.2% of the
GFP-J774A.1 cells, whereas cells treated with EP only or Cas9–
Gfp sgRNA only or without any treatment remained GFP-pos-
itive in virtually all of the cells (Fig. 2B).
To optimize the gene deletion efficiency of CriPs in GFP-
J774A.1 cells, we first determined the relationship between
CriP dose and response by changing the concentrations of the
Cas9–Gfp sgRNA complexes. GFP loss was observed in about
50% of theGFP-J774A.1 cells treatedwithin the range of a 100–
300 nM concentration of the Cas9–Gfp sgRNA complexes (Fig.
2C). We next tested the effect of the Cas9–sgRNA molar ratio
on the gene deletion efficiency. A maximum loss of GFP in
53.3% of the GFP-J774A.1 cells was observed in response to
CriPs loadedwith a 1:1molar ratio of Cas9 andGfp sgRNA (Fig.
2D). By assessing the effect of EP concentration onGfp deletion
efficiency, a maximum GFP loss in 53.4% of the GFP-J774A.1
cells was observed with 2 M EP (Fig. 2E), which is the highest
concentration of EP that was not associated with detectable
cytotoxicity (Fig. S3).
To confirm that the loss of GFP in the GFP-J774A.1 cells was
due to genome engineering by the CriPs targeting theGfp gene,
the frequency of indel mutations in the Gfp genomic locus was
determined by a T7E1 assay. The cells treated with CriPs tar-
geting Gfp (Cas9–Gfp sgRNA–EP) showed 40.4% of indels in
the Gfp genomic locus, whereas the cells treated with EP alone
showed only background noise (Fig. 2F). T7E1 assay usually
underestimates the mutation frequencies due to the efficiency
of the PCR and the cleavage property of the T7 endonuclease I
(53). T7E1 recognizes and cleaves nonperfectly matched DNA
at the first, second, or third phosphodiester bond that is
upstream of the mismatch. T7E1 cleaves heteroduplex DNA
but does not recognize homozygous mutations, completely
ignores single polymorphisms (SNPs), and also tends to miss
small indels (53).
Comparison of CriPs versus Lipofectamine RNAiMAX in vitro
To compare the gene deletion efficiency by CriPs versus
Cas9–sgRNA delivered by commercially available transfect
agents, we treated the GFP-J774A.1 cells with either CriPs
loaded with Gfp sgRNA or Cas9–Gfp sgRNA plus Lipo-
fectamineRNAiMAX. At two time points, 48 h or 5 days post-
treatment of Cas9–Gfp sgRNA–RNAiMAX, a GFP shift or loss
was observed, as determined by flow cytometry in 29.4 and
29.8% of GFP-J774A.1 cells, respectively (Fig. 2G and Fig. S2).
Table 1
Size and charge measurements of particles
Diameter Polydispersity index Charge
nm mV
EP 0.8 0.2 0.272 18.0 5.5
Cas9 9.3 2.6 0.655 13.9 6.8
Cas9–sgRNA (1:1) 14.3 3.2 0.605 2.4 3.8
Cas9–sgRNA–EP (1:1:20) 375 47 0.930 6.0 4.4
Cas9–sgRNA–EP (1:1:150) 1098 163 0.580 14.6 6.3
Cas9–sgRNA–EP (1:1:250) 1285 201 0.635 20.7 6.0
Cas9–sgRNA–EP (1:1:20) in DMEM 347 50 0.974 NAa
Cas9–sgRNA–EP (1:1:150) in DMEM 1270 192 0.501 NA
Cas9–sgRNA–EP (1:1:250) in DMEM 1489 283 0.387 NA
aNA, not applicable.
Cas9–sgRNA delivery particles for gene deletion
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Cas9–Gfp sgRNA delivered by Lipofectamine RNAiMAX
showed less Gfp gene deletion efficiency compared with CriPs,
which showed a GFP loss in over 50% of cells (Fig. 1B). To
optimize the gene deletion efficiency of Cas9–Gfp sgRNA
delivered by Lipofectamine RNAiMAX in GFP-J774A.1 cells,
the concentrations of the Cas9–Gfp sgRNA complexes (Fig. S2,
B and D) and the molar ratio of the Cas9–Gfp sgRNA com-
plexes were optimized (Fig. S2, E and F). A maximum loss of
GFP was observed in 20–30% of the GFP-J774A.1 cells treated
with the range of a 100–300 nM concentration of the Cas9–Gfp
sgRNA complexes at molar ratios of 1:1 to 1:5. These experi-
ments suggest that Gfp gene deletion by Cas9–Gfp sgRNA
delivered using Lipofectamine RNAiMAXwas not as efficient
as the CriPs in GFP-J774A.1 cells (Fig. 1 (A–E) and Fig. S1).
Gfp deletion in primary white pre-adipocytes fromGFPmice
To investigate whether CriPs can efficiently delete genes in
primary pre-adipocytes in vitro, primary pre-adipocytes were
isolated from GFP transgenic heterozygous mice and treated
withCriPs loadedwithGfp sgRNAor control CriPs loadedwith
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cytometry and T7E1 assays were performed to measure the loss of GFP. A, 48 h post-treatment, GFP loss measurements by flow cytometry. B, 5 days
post-treatment, GFP loss measurements by flow cytometry. Concentrations were as follows: Cas9, 150 nM; Gfp sgRNA, 150 nM; EP, 2 M. C, different concen-
trations of Cas9–Gfp sgRNA (1:1) with 2 M EP. D, different ratios of Cas9 (200 nM) to Gfp sgRNA with 2 M EP. E, different concentrations of EP with 200 nM
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a control, nontargeting sgRNA (control sgRNA). CriPs were
formulated in two different buffer systems, NEBuffer 3 and
PBS. CriPs were then incubated with primary GFP white pre-
adipocytes. On day 5 post-treatment, the loss of GFP signal was
determined by flow cytometry. Formulated in NEBuffer 3 (100
mMNaCl, 50 mM Tris-HCl, 10 mMMgCl2, 1 mM DTT, pH 7.9),
CriPs loaded withGfp sgRNA (Cas9–Gfp sgRNA–EP) induced
a loss of the GFP signal in 48.5% of the GFP pre-adipocytes,
whereas the control CriPs (Cas9–control sgRNA–EP) showed
only a background noise of 0.84% of the negative GFP pre-
adipocytes (Fig. 3A). To optimize the EP dose that causes the
maximum gene deletion efficiency of Gfp by CriPs formulated
in NEBuffer 3 in the primary GFP pre-adipocytes, the relation-
ship between EP dose and response was determined. A maxi-
mum GFP loss was achieved in about 43.7  3.0% of the GFP
pre-adipocytes when the Cas9–Gfp sgRNA complexes (100
nM) were coated with 30 M EP (Fig. 3B). Interestingly, the loss
of GFP was not complete after 5 days post-transfection, as flow
cytometry analysis showed amixed population of cells that dis-
played either a complete loss of GFP, a shift in GFP loss, or no
GFP loss. These variations can possibly be explained by the fact
that the GFP transgenic mice likely have multiple Gfp trans-
genes inserted into their genome (54).
When CriPs were formulated in PBS (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), a loss of the
GFP signal in 35.1% of the GFP pre-adipocytes was observed
when treated with CriPs targetingGfp (Cas9–Gfp sgRNA–EP),
whereas the control CriPs (Cas9–control sgRNA–EP) showed
a background of 1.05% loss (Fig. 3C). The dose–response rela-
tionship of EP indicated a maximum GFP loss in about 35.8
0.8% of the primary GFP pre-adipocytes treated with the CriPs
loaded with the Cas9–Gfp sgRNA complexes (100 nM) coated
with 15 M EP (Fig. 3D). Thus, the gene deletion efficiency
depends on the formulations of the CriPs in different buffer
systems coated with different doses of EP.
To confirm that the loss of the GFP in the primary GFP pre-
adipocytes was due to genome engineering by the CriPs target-
ing the Gfp gene, we performed a T7E1 assay to determine the
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concentrations of EP with 100 nM of Cas9–sgRNA formulated in NEBuffer 3 (B) or PBS (D). E, percentage indel measurements by a T7E1 assay in genomic DNA
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mutation frequency of indels in the Gfp genomic locus. Com-
pared with the cells treated with control CriPs, cleaved prod-
ucts were observed in the cells treated with CriPs targetingGfp
(Cas9–Gfp sgRNA–EP) with a mutation frequency of 14.4%
(Fig. 3E). This is probably due to the multiple copies of GFP
transgenes inserted into the genome (54) as well as an underes-
timation caused by the T7E1 assay (53). These results indicate
that efficient genome targeting can be achieved by treatment
with CriPs in primary pre-adipocytes in vitro.
Deletion of Gfp in PECs isolated fromGFP transgenicmice
To determine the gene deletion efficiency using CriPs in pri-
mary GFP PECs, primary PECs that stably express GFP were
isolated fromGFP transgenic heterozygous mice that had been
injected with thioglycollate broth. The PECs were treated with
CriPs loaded with Gfp sgRNA or control CriPs loaded with
control sgRNA.On day 5 post-treatment, the loss of GFP signal
was determined by flow cytometry. Compared with control
CriPs that showed a background shift of 2.88% (Fig. 4A), CriPs
loaded with Gfp sgRNA (Cas9–Gfp sgRNA–EP) showed a
decrease of theGFP signal in 40.7%of theGFP-expressing PECs
(Fig. 4B). The relationship between Cas9–sgRNA dose and
response indicated a maximum GFP loss of about 35.2 4.0%
in the GFP-expressing PECs when the CriPs were loaded with a
100 nM concentration of the Cas9–Gfp sgRNA complexes
coated with 2 M EP (Fig. 4C). The T7E1 assay showed a muta-
tion frequency of 32.8% in theGfp genomic DNA isolated from
the cells treated with CriPs targeting Gfp, compared with a
background of 2.4% in the cells treated with the control CriPs
(Fig. 4D).
Deletion of Gfp by delivery of CriPs in vivo to GFPmice
To determine the ability of CriPs to systemically deliver
Cas9–sgRNARNPs in vivo to achieve gene deletion, we admin-
istrated CriPs to mice by i.p. injections. Shown in Fig. 5A, GFP
transgenic heterozygous mice were intraperitoneally injected
daily for 5 days with CriPs targetingGfp (CriPs–Gfp sgRNA) or
with control CriPs (CriPs–control sgRNA). On day 6, mice
were sacrificed, and PECs were collected and plated in cell cul-
ture. On day 13, flow cytometry was performed to measure the
loss of GFP signal. Deep sequencing was also performed to
detect the indels in the Gfp genomic locus. Measured by flow
cytometry, a loss of the GFP signal was observed in the range of
2.9–13.9% of the PECs (average 5.70 1.07%) isolated from 10
GFP transgenic heterozygous mice injected with CriPs–Gfp
sgRNA. This was significantly greater than the 1% GFP loss
we observed in the CriPs–control sgRNA–treated mice (aver-
age 0.74 0.05%) (Fig. 5, B and C).
To confirm that the deletion ofGFPwas due to genome engi-
neering of Gfp by CriPs–Gfp sgRNA as well as to study the
mutation composition of the insertions and deletions in theGfp
genomic locus, we performed deep sequencing on the PCR
amplicons amplified from the genomic DNA isolated from
PECs. Approximately 3% of the target sequences were mutated
in the CriPs–Gfp sgRNA–injected samples, corroborating the
data on the GFP loss measured by flow cytometry shown in Fig.
5B, whereas only a background noise of 0.02% was observed in
the CriPs–control sgRNA–injected samples. To study the
composition of the mutations in the Gfp genomic locus of the
CriPs–Gfp sgRNA–injected samples, the DNA sequences of
the GFP WT and the mutants were aligned (Fig. 5D). The
mutants consisted of sequenceswith insertions and deletions of
the bases as well as SNPs in the target site.
Taken together, significant gene deletion of theGfp gene was
achieved by i.p. injections of the CriPs targeting Gfp in vivo in
the GFP transgenic heterozygous mice, as determined by both
flow cytometry and deep sequencing. This is likely an underes-
timate of the efficiency because GFP expressing transgenic
mice are predicted to have multiple GFP transgenes inserted
into their genome (54). A higher genome-engineering effi-
ciency would be expected when editing an endogenous target
gene of interest that is present in two copies.
Analysis of immune response inmice injected with CriPs
To examine the possibility of an immune response and sys-
tematic inflammation induced by CriPs, we intraperitoneally
injected WT mice daily for 5 days with CriPs loaded with a
nontargeting sgRNAor PBS as a control. The systemic cytokine
profile was analyzed by measuring cytokine levels (IL-1, IL-4,
IL-6, IL-10, IFN, and TNF) in the plasma before injection
and then 24 h and 2 weeks after the first injection. The plasma
cytokine levels (IL-10 and TNF) in mice treated with LPS for
1.5 h were also measured to serve as a positive control for the
assay (Fig. 6D).
Shown in Fig. 6A, low background levels of inflammatory
cytokines were observed before i.p. injection of CriPs and PBS
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Figure 4. Efficient gene deletion achieved following treatment with
CriPs targetingGfp inprimaryPECs isolated fromthioglycollate-injected
GFP mice. 5 days post-treatment, flow cytometry and T7E1 assay were per-
formed to measure the loss of GFP. A and B, flow cytometry data of primary
GFP PECs treated with CriPs with a control, nontargeting sgRNA sequence
(Cas9–control sgRNA–EP) (A) and CriPs targeting Gfp (Cas9–Gfp sgRNA–EP)
(B) (Cas9, 100 nM; sgRNA, 100 nM; EP, 2 M). C, different concentrations of
Cas9–sgRNA (1:1) with 2 M EP. D, percentage indel measurements in Gfp
genomic DNA isolated from CriPs-treated primary GFP PECs by a T7E1 assay
(uncut, 401 bp; cut, 288 bp 113 bp; Cas9, 100 nM; sgRNA, 100 nM; EP, 2M).
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in mice. Systemic injections of CriPs did not cause an acute (24
h) or a chronic (2 weeks) up-regulation of inflammatory cyto-
kines, such as IL-1, IL-4, IL-10, IFN, andTNF, in the plasma
(Fig. 6, B and C), suggesting the absence of a broad immune
response uponCriP administration under the conditions of our
experiments. Interestingly, the level of IL-6was increased in the
plasma 24 h after the first injection in mice treated with CriPs.
IL-6 acts as both a pro-inflammatory cytokine and an anti-in-
flammatory myokine (55). It can be significantly elevated by
many factors, such as exercise (56). More importantly, IL-6
returned to a low background level when it was measured 2
weeks after the first injection. In addition, the low levels of all of
the plasma inflammatory cytokines measured 10 days after a
total of five injections (2 weeks after the first injection) indi-
cated that CriPs can be administrated multiple times systemi-
cally in vivo without chronic toxicity (Fig. 6C).
Deletion of Nrip1 in primary pre-adipocytes enhances
browning
Targeting genes in adipocytes that suppress mitochondrial
uncoupling and fatty acid oxidation is a potential strategy to
enhance adipocyte browning and energy expenditure (38). Our
laboratory has used RNAi-based screens in cultured adipocytes
to identify such genes that control insulin sensitivity and energy
metabolism (44). An exciting “hit” in these screens of several
thousand genes was the nuclear co-repressorNrip1 (44), which
was also discovered in independent studies inmice (46). NRIP1
interacts with nuclear receptors to suppress their activities to
regulate genes that control glucose utilization, mitochondrial
function, fatty acid oxidation, and secretion of beneficial factors
(44). We and others have found that the depletion of NRIP1 in
adipocytes and in mice increased fatty acid oxidation, mito-
chondrial respiration, insulin sensitivity, and glucose tolerance
Figure 5. Efficient gene deletion achieved by i.p. injections of CriPs targetingGfp in GFPmice. A, timeline of i.p. administration of CriPs to GFPmice. GFP
transgenic mice were intraperitoneally injected daily for 5 days with CriPs targeting Gfp (CriPs–Gfp sgRNA) or control CriPs (CriPs–control sgRNA). On day 6,
mice were sacrificed, and PECs were collected and plated in cell culture. On day 13, flow cytometry and deep sequencingwere performed tomeasure the loss
of GFP. B, flow cytometry data showing GFP loss in mice injected with CriPs–Gfp sgRNA or CriPs–control sgRNA. C, quantification of flow cytometry data
(3–8-week-oldGFPmaleC57BL/6mice,n10).D, indels in theGfp locusofCriPs–Gfp sgRNA–injected samplesbydeep sequencing. ShownareDNAsequences
of the GfpWT andmutants. PAM is underlined. The cleavage site is indicated by an arrowhead. The column on the right indicates the number and frequencies
of inserted () or deleted () bases or SNPs (S). Error bars, S.E.
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(44, 46, 57). Therefore, NRIP1 presents a potential therapeutic
target for type 2 diabetes and other metabolic disorders.
To investigate whether the Nrip1 gene can be efficiently
deleted in adipocytes and whether the depletion of Nrip1 can
lead to the enhanced expression of genes associatedwith energy
expenditure, such as UCP1, we isolated primary white pre-adi-
pocytes from WT mice and treated them with CriPs loaded
with each of four different sgRNAs targeting Nrip1 (Nrip1
sgRNA 1,Nrip1 sgRNA 2,Nrip1 sgRNA 3, andNrip1 sgRNA 4)
or control groups (CriPs–control sgRNA, Cas9–EP, EP only,
and nontreated). The treated pre-adipocytes were then differ-
entiated to mature adipocytes using a differentiation mixture.
On day 8 post-differentiation, cells were collected to measure
both the frequency of indels in the Nrip1 genomic locus by a
T7E1 assay and the expression of UCP1 by RT-PCR.
Indicated by a T7E1 assay (Fig. 7A), four CriP formulations,
each loaded with a different sgRNA targeting Nrip1, showed
indels in the Nrip1 genomic locus with different degrees of
mutation frequencies. CriPs loaded with Nrip1 sequence 3
(Nrip1 sgRNA3) demonstrated the highestmutation frequency
of 43.8% in the Nrip1 genomic locus. More importantly, the
deletion of the Nrip1 gene in the white adipocytes caused
the browning of cells, evidenced by increased expression of the
uncoupling protein UCP1. Indeed, UCP1 was significantly
increased in response to all four CriP formulations loaded with
different sgRNAs targeting Nrip1. Adipocytes treated with
CriPs loadedwith theNrip1 sgRNA3,whichwasmost potent in
deleting the Nrip1 gene measured by the T7E1 assay (Fig. 7A),
elicited themostmarked increase inUCP1 expression (Fig. 7B).
The expression of other thermogenic genes, inflammatory
genes, and neurotropic factors were also measured by RT-PCR
in the white adipocytes that had been treated with Cas9–Nrip1
sgRNA 3–EP and Cas9–control sgRNA–EP. Thermogenic
genes involved in adipocyte browning (Ucp1, Cidea, Pgc1,
Prdm16, andCpt1b) were increasedwith the treatment of CriPs
loaded with Nrip1 sgRNA 3, compared with the control CriPs
(Fig. 7C). Neurotrophic factors (Nrg4, Nnat, and Nrn1) were
also increasedwith the treatment of CriPs–Nrip1 sgRNA3 (Fig.
7E), whereas inflammatory genes (Il1, Il4, Il6, Il10, andMcp1)
were not changed between CriPs–Nrip1 sgRNA 3 and CriPs–
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Figure 6. Plasma cytokine levels weremeasured inmice intraperitoneally injectedwith CriPs in vivo.WTmicewere intraperitoneally injected daily for 5
days with PBS or CriPs loaded with a nontargeting sgRNA. Plasma was collected before injection and then 24 h and 2 weeks after the first injection. Plasma
cytokine levels (IL-1, IL-4, IL-6, IL-10, IFN, andTNF)weremeasuredbyLuminex. Plasmacytokine levelsweremeasuredbefore injection (A), 24hafter the first
injection (B), and 2 weeks after the first injection (C). D, plasma cytokine levels (IL-10 and TNF) were also measured in the mice treated with LPS at 1.5 h
postinjection (p.i.) or without LPS to serve as positive controls for the assay. Data are means S.E. (error bars) (n 3–4).
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control sgRNA groups (Fig. 7D). Overall, these results indicate
that efficient Nrip1 gene deletion was achieved in white adi-
pocytes treated with CriPs targeting Nrip1, and the deletion of
theNrip1 gene byCriPs converts thewhite adipocytes to amore
“brown” adipocyte phenotype known to be beneficial to whole-
body metabolism in mice.
Off-target effects of CriPs targeting Nrip1 in adipocytes
Primary pre-adipocytes were treated with CriPs loaded with
Nrip1 sgRNA 3, which caused the highest mutation frequency
in theNrip1 genomic locus andmost increased UCP1 in differ-
entiated adipocytes, as indicated in Fig. 7. Differentiated adi-
pocytes were collected to measure the mutation frequencies in
the on-target Nrip1 genomic locus and the off-target genomic
sites. All of the off-target sequences contained three mismatch
bases compared with the on-target sequence and were located
in the intergenic regions. Determined by a T7E1 assay, no obvi-
ous off-target effects in the adipocytes treated with CriPs tar-
getingNrip1were observed comparedwith the nontreated cells
(Fig. 8).
Discussion
A key challenge to realizing the potential of CRISPR-Cas9–
based therapeutics is the assurance of safe and effective delivery
to target cells (6, 9). The major advance of this study is the
development of a novel and simple system, CriPs, to efficiently
deliverCRISPR-Cas9–based reagents in vitro and in vivo. CriPs
consist of three components (Cas9 protein, sgRNA targeting
genes of interest, and the EP peptide), which facilitate transport
of large cargoes across cell membranes (Fig. 1). As a therapeutic
approach, the direct delivery of Cas9 in protein form enables
the swiftest gene editing, as there is no need for transcription or
translation of the nuclease (7). Direct delivery of Cas9 protein
offers advantages over plasmid delivery and viral delivery,
which can display uncontrolled integration of DNA segments
into the host genome, unwanted immune responses to the plas-
mids and virus, and limited packaging capacity (6). It has been
shown that the Cas9 protein introduced into cells rapidly
degrades within 24 h (52), eliminating immune responses using
an ex vivo therapeutic approach, where implantation of engi-
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Figure 7. CriPs-mediatedNrip1deletion inwhite adipocytes increases the expressionofUCP1. Primary pre-adipocyteswere treatedwith CriPswith each
of fourdifferent sgRNAs targetingNrip1 (Nrip1 sgRNA1,Nrip1 sgRNA2,Nrip1 sgRNA3, andNrip1 sgRNA4) andcontrols. Pre-adipocyteswere thendifferentiated
intomature white adipocytes (Cas9–sgRNA, 100 nM; EP, 25M). A, indel detection inNrip1 genomic DNAwas determined by a T7E1 assay. DNA bands were as
follows: Nrip1 sgRNA 1: uncut, 429 bp; cut, 283 bp 146 bp; Nrip1 sgRNA 2: uncut, 334 bp; cut, 223 bp 111 bp; Nrip1 sgRNA 3: uncut, 420 bp; cut, 150 bp
270bp;Nrip1 sgRNA4: uncut, 381bp; cut, 307bp74bp.B, UCP1expressionwasmeasuredbyRT-PCR.C–E, with the treatment of Cas9–Nrip1 sgRNA3–EPand
Cas9–control sgRNA–EP, gene expression was measured by RT-PCR. C, thermogenic genes; D, inflammatory genes; E, neurotrophic factors. Error bars, S.E.
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neered cells is performed days after gene deletion. Because
CriP-mediated gene editing lasts for the lifespan of a cell (e.g. up
to 10 years for adipocytes) (58), infrequent administration of
engineered cell implants would be required to maintain thera-
peutic efficacy.
Characterized by DLS (Table 1), the CriPs composed of
Cas9–sgRNA–EP (1:1:20) showed a hydrodynamic size of
375 47 nmwith a positive  potential. Compared with Cas9–
sgRNA (1:1) alone with a hydrodynamic size of 14.3 3.2 nm,
the increase of size indicates the formation of CriPs containing
multiple Cas9–sgRNA complexes associated with EP peptides.
The overall positive charge on the surface of the particles is
predicted to facilitate the cellular uptake by interactingwith the
negatively charged cell membranes. The sizes and the positive
charges of CriPs were further increased when Cas9–sgRNA
nanocomplexes were exposed to higher EP concentrations.
Interestingly, the unchanged size of CriPs when exposed to
DMEM suggests stability of the particles in culture medium.
The present study demonstrates that CriPs facilitate efficient
gene deletion of the proof-of-concept gene Gfp in multiple cell
types, including GFP-J774A.1 cells (Fig. 2), GFP-PECs (Fig. 4),
and primary GFP-expressing pre-adipocytes (Fig. 3). We
observed GFP loss in about 50% of cells treated with CriPs tar-
getingGfp, detected by flow cytometry analysis (Figs. 2 (A–E), 3
(A–D), and 4 (A–C)) and confirmed by identification of indels
in theGfp genomic locus by a T7E1 assay (Figs. 2F, 3E, and 4D).
We found that the EP concentration that is optimal formaximal
gene deletion is highly cell type–dependent (Figs. 2E and 3 (B
andD)). Primary pre-adipocytes require a much higher dose of
EP to achieve maximum gene deletion compared with macro-
phages. On the contrary, high doses of EP are toxic to macro-
phages but not to primary pre-adipocytes (Fig. S3). Gene dele-
tion efficiency also depends on the formulations of the CriPs in
different buffer systems (Fig. 3, A–D), such as NEBuffer 3 (100
mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9)
and PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, pH 7.4), possibly due to salts and pH levels that affect
the activity of the Cas9 protein and the electrostatic association
of the Cas9–sgRNA nanocomplex and EP. In addition, CriPs
demonstrate higher gene deletion efficiency in GFP-J774A.1
cells compared with the Cas9–sgRNA delivered by commer-
cially available Lipofectamine RNAiMAX (Fig. 2, G and H).
Althoughmany delivery systems have been used to edit genes
by Cas9–sgRNARNPs in cell culture (30, 33), primary cells (15,
19), and local areas of animals, such as inner ear (4, 23), skin
(18), tumor (28), muscle (29), and brain (35), systemic delivery
of Cas9–sgRNA RNP complexes using a fully nonviral system
has not been previously demonstrated. To determine the ability
of CriPs to delete genes in vivo by systemic delivery, we per-
formed five daily i.p. injections of CriPs targeting Gfp (CriPs–
Gfp sgRNA) or control CriPs (CriPs–control sgRNA) in GFP
transgenic heterozygous mice (Fig. 5A). These mice showed a
loss of theGFP signal in 2.91–13.90% of the PECswhen injected
withCriPs–Gfp sgRNA,whichwas significantly higher than the
CriPs–control sgRNA–treated group (average 0.74% 0.05%)
(Fig. 5, B and C). We also confirmed that about 3% of the target
sequences were mutated in the CriPs–Gfp sgRNA–injected
animals, and the mutants were composed of insertions and
deletions of the bases as well as SNPs (Fig. 5D). This is likely an
underestimate of the targeting efficiency because GFP trans-
genic mice likely have multiple Gfp transgenes inserted into
their genome (54). Taken together, our work demonstrates a
simple nonviral genome editing system that delivers Cas9–
sgRNA RNPs systemically in vivo to achieve significant gene
deletion.
On-Target Oﬀ-Target 1 Oﬀ-Target 2 Oﬀ-Target 3
Nrip1
On-Target GGAGTCGAAGAACATCTGCATGG
Oﬀ-Target 1 GGACTATAAGAACATCTGCATGG
Oﬀ-Target 2        GGAGATGAAGAACATGTGCATGG
Oﬀ-Target 3        GGAGAAGAAGAACCTCTGCATGG
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Figure 8. Determination of off-target effects of CriPs targeting Nrip1 by a T7E1 assay. Primary pre-adipocytes were treated with CriPs with Nrip1 sgRNA
3. Pre-adipocytes were then differentiated into mature white adipocytes. Top off-target candidate sites were determined by the CHOPCHOP program.
Off-target effects were determined by a T7E1 assay. Expected DNA bands cleaved by T7E1 were as follows: on-target: uncut, 420 bp; cut, 270 bp 150 bp;
off-target 1: uncut, 386 bp; cut: 283 bp 103 bp; off-target 2, uncut: 387 bp; cut, 229 bp 158 bp; off-target 3: uncut, 352 bp; cut: 182 bp 170 bp. TGG in
boldface type, the PAM site. Mismatch sites are underlined and in boldface type.
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Gene editing or deletion in adipose tissue to enhance adipose
tissue energy expenditure and fatty acid oxidation through a
browning process presents a potential therapeutic approach to
alleviate obesity and type 2 diabetes (38, 41). Brown adipocytes
not only generate heat but also secrete beneficial factors that
enhance glucose tolerance in mice (39, 43). We demonstrate
the utility of CriP-mediated gene deletion of Nrip1 in white
adipocytes, demonstrating an induced browning phenotype
with remarkably enhanced expression of UCP1, known to
uncouple mitochondrial respiration, activate fatty acid oxida-
tion, and improve glucose tolerance (Fig. 7). UsingCriPs target-
ingNrip1 in the white adipocytes, we observed a highest muta-
tion frequency of 43.8% in theNrip1 genomic locus withNrip1
sgRNA 3 measured by a T7E1 assay (Fig. 7A). Adipocytes
treated with the CriPs–Nrip1 sgRNA 3, which were most
potent in deleting the Nrip1 gene, demonstrated the most
marked increase in UCP1 expression (Fig. 7B). Other thermo-
genic genes (Ucp1,Cidea, Pgc1, Prdm16, andCpt1b) and neu-
rotrophic factors (Nrg4, Nnat, and Nrn1) were also increased
(Fig. 7, C and E). In addition, off-target effects in adipocytes
treatedwithCriPs–Nrip1 sgRNA3were not detected by aT7E1
assay (Fig. 8). Thus, the CriPs loaded with sgRNA targeting
Nrip1 provide significant potential for therapeutic develop-
ment to alleviate metabolic disease.
Experimental procedures
Materials
All chemicals were purchased from Sigma-Aldrich unless
otherwise specified andwere used as received. Cas9 proteinwas
purchasedfromPNABIO, Inc. (NewburyPark,CA).DNAoligo-
nucleotides were purchased from Integrated DNA Technolo-
gies Inc. (Coralville, IA). The MEGAshortscript T7 transcrip-
tion kit, Lipofectamine RNAiMAX, Vybrant MTT cell
proliferation assay, and PlatinumTM TaqDNA Polymerase
High Fidelity kit were purchased from Thermo Fisher Scien-
tific. BsaI, DraI, T7E1, andNEBuffer 3 were obtained fromNew
England Biolabs Inc. (Ipswich,MA). pUC57-sgRNA expression
vector was purchased from Addgene (plasmid 51132) (Cam-
bridge, MA). EP was purchased from Gene Tools (Philomath,
OR). The QIAquick PCR purification kit was purchased from
Qiagen Inc. (Valencia, CA). 4–20% Mini-Protean TBE gel was
purchased from Bio-Rad. 7-AAD was purchased from BD Bio-
sciences. Insulin was purchased from Cell Application (San
Diego, CA). Dexamethasone, isobutylmethylxanthine, indo-
methacin, and lipopolysaccharide (LPS) were purchased from
Sigma. Rosiglitazone was purchased from Cayman Chemical
(Ann Arbor, MI).
Preparation of sgRNA template and synthesis of sgRNA
sgRNA sequences were designed using sgRNADesigner (59)
developed by the Broad Institute and the CHOPCHOP pro-
gram (60, 61) developed by Harvard University. Templates for
sgRNAs were generated by inserting annealed complementary
oligonucleotides with the sgRNA sequences into the pUC57-
sgRNA expression vector encoding a T7 promoter. The sgRNA
templates were linearized byDraI and transcribed in vitro using
the MEGAshortscript T7 transcription kit according to the
manufacturer’s instructions. Transcribed sgRNA was resolved
on a 10% denaturing urea-PAGE to check the size and purity.
sgRNA sequences are listed in Table S1.
Preparation of the CriPs
Purified bacterial Cas9 protein is processed to remove endo-
toxin and other contaminants and is used for loading of sgRNA.
The powder ofCas9 proteinwas resuspended inwaterwith 20%
glycerol. Cas9 protein and sgRNA were mixed in NEBuffer 3
(100 mMNaCl, 50 mM Tris-HCl, 10 mMMgCl2, 1 mMDTT, pH
7.9) purchased fromNew England Biolabs Inc. or PBS (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4)
at 37 °C for 10 min to form nano-size complexes. The loaded
Cas9–sgRNA nanocomplexes are then complexed with EP in
PBS at room temperature for 15 min to form the final CriPs.
Characterization of the CriPs
The size of CriPs was determined by DLS (laser wavelength
633 nm) using a Malvern Zetasizer Nano-ZS particle size ana-
lyzer (Malvern Instruments,Worcestershire, UK). Solvents and
buffers were filtered through 0.22-m filters before sample
preparation. EP (1 mM), Cas9 (1M), Cas9–sgRNA (1M), and
CriPs (1M) with different ratios of EP weremeasured for sizes
upon the absence or presence of DMEM (GE Healthcare). 
potentials of CriPs were also determined with a Malvern Zeta-
sizer Nano-ZS using a Universal “Dip” Cell Kit. Solvents and
buffers were filtered through 0.22-m filters before sample
preparation. A suspension of samples was diluted in 20 mM
HEPES buffer for the measurement. Data were analyzed with
the Dispersion Technology software (Malvern).
Cell lines and culture
J774A.1 cells were acquired from ATCC (Manassas, VA).
J774A.1 cells stably expressing GFP (a gift from Dr. H. Yang,
University of Massachusetts Medical School, Worcester, MA)
were maintained in DMEM supplemented with 10% (v/v) fetal
bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA),
100 g/ml streptomycin, and 100 units/ml penicillin (Thermo
Fisher Scientific). Cell incubations were performed in a water-
jacketed 37 °C/5% CO2 incubator.
In vitro CriPs treatment in GFP-J774A.1 cells
GFP-J774A.1 cells were plated in 12-well plates with 1 105
cells/well overnight. Cells were treated with CriPs loaded with
Gfp sgRNA (Cas9–Gfp sgRNA–EP) or controls such as Cas9–
Gfp sgRNA without EP, EP only, and nontreated. After 24 h,
medium containing CriPs and controls was replaced with fresh
culture medium. At 48 h or on day 5 post-treatment, flow
cytometry analysis was performed to measure the loss of GFP.
7-AAD staining was used to determine live cells and dead cells.
The percentages of GFP-negative cells and GFP-positive cells
were calculated from the live cells in the flow cytometry analy-
sis. Indels in the Gfp genomic locus were measured by a T7E1
assay.
Transfection of GFP-J774A.1 with Cas9–sgRNA using
RNAiMAX
GFP-J774A.1 cells were plated in 12-well plates with 1 105
cells/well overnight. Cells were treated with Cas9–Gfp sgRNA
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complexes delivered by LipofectamineRNAiMAXor controls
such as Cas9–Gfp sgRNA without RNAiMAX, RNAiMAX
only, and nontreated. After 24 h, cells were fed with fresh cul-
ture medium. At 48 h or on day 5 post-treatment, flow cytom-
etry analysis was performed tomeasure the loss of GFP. 7-AAD
staining was used to determine live cells and dead cells. The
percentages of GFP-negative cells and of GFP-positive cells
were calculated from the live cells analyzed by flow cytometry.
Animals
All mice were purchased from Jackson Laboratory.WTmice
(C57BL/6J) and GFP transgenic heterozygous mice (C57BL/6-
Tg(UBC-GFP)30Scha/J) were used for the experiments. Mice
were housed on a 12-h light/dark schedule and had free access
to water and food. All procedures involving animals were
approved by the institutional animal care and use committee at
the University of Massachusetts Medical School.
Isolation of primary PECs fromGFP transgenicmice
Ten-week-old GFP transgenic heterozygous mice were
intraperitoneally injected with 4% thioglycollate broth (Sigma-
Aldrich). Five days following injection, themicewere sacrificed,
and the peritoneal cavity was washed with 5 ml of ice-cold PBS
to isolate PECs. Peritoneal fluid was filtered through a 70-m
pore nylon mesh and centrifuged at 1200 rpm for 10 min. The
pellet was first treated with red blood cell lysis buffer (8.3 g of
NH4Cl, 1.0 g ofKHCO3, and 0.037 g of EDTAdissolved in 1 liter
of water) and resuspended in DMEM supplemented with 10%
(v/v) FBS, 100g/ml streptomycin, and 100 units/ml penicillin.
In vitro CriPs treatment of primary GFP PECs
Primary GFP PECs isolated from GFP transgenic mice were
plated in 12-well plates with 5 105 cells/well overnight. Cells
were treated with CriPs loaded with Gfp sgRNA or control
sgRNA. After 24 h, cells were fed with fresh culture medium.
On day 5 post-treatment, flow cytometry analysis was per-
formed tomeasure the loss of GFP. 7-AAD staining was used to
determine live cells and dead cells. The percentages of GFP-
negative cells and GFP-positive cells were calculated from the
live cells analyzed by flow cytometry. Indels in theGfp genomic
locus were measured by a T7E1 assay.
Culture of primary white pre-adipocytes frommice
Three-week-old GFP transgenic heterozygous mice or WT
mice were sacrificed, and inguinal subcutaneous fat pads were
dissected out and placed into Hanks’ balanced salt solution
(withoutCa2) with 3%BSA.Tissuesweremincedwith scissors
to 3–5-mm pieces. Tissues were digested in collagenase D
solution (2 mg/ml collagenase D in Hanks’ balanced salt solu-
tionwith 3%BSA) in a 37 °Cwater bath shaker for 1 hwith short
vortex every 10–15 min. Samples were inactivated with 10%
FBS, filtered through a 100-mmesh, and centrifuged at 600
g for 5 min. The stromal vascular fraction pellet was resus-
pended in red blood cell lysis buffer for 5 min and centrifuged
again at 600  g for 5 min. Cell pellet was resuspended in
DMEM/F-12mediumwith 10%FBS and 1% streptomycin/pen-
icillin, filtered through 40-m mesh, and plated. Medium was
replaced every 2 days until cells reached 100% confluence
before differentiation. Cells were differentiated by adding the
differentiation mixture (5 g/ml insulin, 1 M dexamethasone,
0.5 mM isobutylmethylxanthine, 60 M indomethacin, 1 M
rosiglitazone). After 48 h, the medium was changed to only
include 1 M rosiglitazone and 5 g/ml insulin. After another
48 h, the medium was changed to include 5 g/ml insulin only.
On day 5 post-differentiation, the cells are considered fully
differentiated.
Treatment ofmouse primary white pre-adipocytes with CriPs
Gfp target gene—PrimaryGFPwhite pre-adipocyteswere iso-
lated from GFP transgenic heterozygous mice and plated in
12-well plates with 8  104 cells/well overnight. Cells were
treated with CriPs loaded with Gfp sgRNA or control CriPs
loadedwith control sgRNA. After 24 h, cells were fed with fresh
culture medium. On day 5 post-treatment, flow cytometry
analysis was performed to measure the loss of GFP. 7-AAD
staining was used to determine live cells and dead cells. The
percentages of GFP-negative cells and GFP-positive cells were
calculated from the live cells analyzed by flow cytometry. Indels
in the Gfp genomic locus were measured by a T7E1 assay.
Nrip1 target gene—Primary white pre-adipocytes were iso-
lated from WT mice and plated in 12-well plates with 8  104
cells/well overnight. Cells were treated with CriPs loaded with
each of four different sgRNAs targetingNrip1 (Nrip1 sgRNA 1,
Nrip1 sgRNA2,Nrip1 sgRNA3, andNrip1 sgRNA4) or control
groups (CriPs–control sgRNA, Cas9–EP, EP only, and non-
treated) (Cas9–sgRNA, 100 nM; EP, 25 M). After 24 h, cells
were fed with fresh culture medium. Once the pre-adipocytes
reached 100% confluence, they were differentiated to adi-
pocytes with the differentiation mixture. On day 8 post-differ-
entiation, cells were collected to measure indels in the Nrip1
genomic locus by a T7E1 assay.
Gene expression of white adipocytes after Nrip1 CriP deletion
Primary white pre-adipocytes were isolated from WT mice
and treated with CriPs loaded with each of the four sgRNAs
targetingNrip1 (Nrip1 sgRNA 1,Nrip1 sgRNA 2,Nrip1 sgRNA
3, and Nrip1 sgRNA 4) or control groups (CriPs–control
sgRNA,Cas9–EP, EP only, and nontreated) (Cas9–sgRNA, 100
nM; EP, 25 M). Once the pre-adipocytes reached 100% conflu-
ence, they were differentiated to adipocytes with the differenti-
ation mixture. On day 8 post-differentiation, cells were col-
lected to measure the expression of UCP1 by RT-PCR. The
expression of other thermogenic genes, inflammatory genes,
and neurotropic factors was also measured in cells treated
with CriPs loaded with Nrip1 sgRNA 3 or control sgRNA by
RT-PCR.
Off-target effects of CriPs targeting Nrip1
Primary white pre-adipocytes were treated with CriPs
(Cas9–sgRNA, 100 nM; EP, 25M) loaded withNrip1 sgRNA 3.
Pre-adipocytes were then differentiated to mature white adi-
pocytes. On day 8 post-differentiation, cells were collected to
measure indels in the Nrip1 genomic locus or at the off-target
sites by a T7E1 assay. Sequences targeting the top off-target
candidate sites were determined by the CHOPCHOP program
(60, 61). Expected DNA bands cleaved by T7E1 were as follows:
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on-target: uncut, 420 bp; cut, 270 bp  150 bp; off-target 1:
uncut, 386 bp; cut, 283 bp 103 bp; off-target 2: uncut, 387 bp;
cut, 229 bp 158 bp; off-target 3: uncut, 352 bp; cut, 182 bp
170 bp. Off-target sequences are listed in Table S3.
Cytotoxicity assay post-CriP treatment in vitro
The cytotoxicity of Cas9–sgRNA coated with different EP
concentrations in different cell types (J774A.1 cells, PECs, and
primary white pre-adipocytes) was examined by the Vybrant
MTT cell proliferation assay. Cells were treated with Cas9–
sgRNA (100 nM) coated with different concentrations of EP.
After 24 h, the particle-containing medium was replaced by
fresh culture medium. After another 24 h, the medium was
changed to fresh culturemediumwithout phenol red, and 10l
of 12mMMTT stock solution was added to eachwell. The plate
was incubated for an additional 4 h at 37 °C in a humidifiedCO2
incubator. Following the 4-h incubation, 100l of the SDS-HCl
solution was added to each well and incubated overnight. The
absorbance of the colored formazan product was recorded at
570 nm using a microplate reader (Tecan Group Ltd.) and nor-
malized to the control group with no treatment. An average of
three determinations were made.
In vivo treatment of GFP transgenicmice with CriPs
GFP transgenic heterozygous mice (male, 3–8 weeks old)
were intraperitoneally injected daily for 5 days with CriPs
loadedwithGfp sgRNAor control sgRNA.TheCriPs contained
0.9 nmol of Cas9 protein, 0.9 nmol of sgRNA, and 20 nmol of EP
for each injection. On day 6, mice were sacrificed, and the peri-
toneal cavity was washed with 5 ml of ice-cold PBS to isolate
PECs. The cells were plated in the medium (DMEM supple-
mented with 10% (v/v) FBS, 100 g/ml streptomycin, and 100
units/ml penicillin) to enrich for macrophages. Fresh medium
was added every 48 h. On day 13 (8 days after the last injection),
adhered cells were collected. Flow cytometry analysis was per-
formed tomeasure the loss of GFP. 7-AAD staining was used to
determine live cells and dead cells. The percentages of GFP-
negative cells and GFP-positive cells were calculated from the
live cells. Genomic DNAs were also collected for detecting
indels by deep sequencing.
Deep sequencing of PECs after in vivo CriP treatment
PECswere isolated fromGFPmice intraperitoneally injected
with CriPs–Gfp sgRNA and CriPs–control sgRNA. The Gfp
genomic region of the CriPs–Gfp sgRNA target sequence was
amplified by PCR using the PlatinumTM TaqDNA Polymerase
High Fidelity kit according to themanufacturer’s protocol. The
amplicons were purified using the QIAquick PCR purification
kit. Libraries were made from the purified amplicons and
sequenced on the Illumina MiSeq instrument (300-bp paired
end) by the University of Massachusetts Medical School Deep
Sequencing Core Facility. Reads were mapped to theGfp refer-
ence sequence, and insertion/deletion/SNP mutations were
determined by the CRISPR-Dav program (62).
Plasma cytokine levels inmice treatedwith CriPs in vivo
WT mice (male, 20 weeks old) were intraperitoneally
injected daily for 5 days with CriPs loaded with a nontargeting
sgRNA (Gfp sgRNA) or PBS. The CriPs contained 0.9 nmol of
Cas9 protein, 0.9 nmol of sgRNA, and 20 nmol of EP for each
injection. Serum was collected at three time points: before
injection, 24 h after the first injection, and 2weeks after the first
injection. Plasma cytokine levels (IL-1, IL-4, IL-6, IL-10, IFN,
of TNF) were measured using a Luminex multiplex assays on
a Lincoplex instrument by the National Mouse Metabolic Phe-
notyping Center at the University of Massachusetts Medical
School. The assays were performed according to the manufa-
cturer’s recommended procedures. Plasma cytokine levels
(IL-10 and TNF) were alsomeasured inmice treated with LPS
for 1.5 h or without LPS to serve as positive controls for the
assay. Data are means S.E. (n 3–4 mice/group).
T7E1 assay
Cells were lysed in cell lysis buffer (1 M KCl, 1 M MgCl2, 1 M
Tris base, pH 8.3, 0.45% Nonidet P-40, 0.45% Tween 20, 0.1
mg/ml proteinase K) and then used as templates in PCRs to
amplify the targeted genomic loci using the PlatinumTM
TaqDNA Polymerase High Fidelity kit according to the man-
ufacturer’s protocol. PCR products were purified using the
QIAquick PCR purification kit and quantified by Nanodrop.
Purified PCR products (200 ng) were mixed with 2 l of 10
NEBuffer 2 (New England Biolabs, Inc.) up to a total volume of
19 l and denatured and then re-annealed with thermocycling
at 95 °C for 5 min, 95 to 85 °C at 2 °C/s, 85 to 20 °C at 0.2 °C/s.
The re-annealed DNA was incubated with 1 l of T7E1 at
37 °C for 15 min. The reaction was stopped by adding 1.5 l
of 0.25 M EDTA and analyzed on a 4–20%Mini-Protean TBE
gel electrophoresed for 1.5 h at 100 V and then stained with
ethidium bromide. The frequency of indels was calculated
based on the band intensities quantified using Image Lab
(Bio-Rad). The intensities of the cleaved bands were divided
by the total intensities of all bands (uncleaved  cleaved) to
determine the frequency of indels to estimate gene modifi-
cation levels. Primer sequences are listed in Tables S2 and
S4.
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